PCM
ECYT

Prelude Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Prelude Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-18,100
Closed -$119K – 2272
2014
Q2 		$119K Sell
18,100
-3,000
-14% -$33.8K 0.02% 1033
2014
Q1 		$502K Buy
+21,100
New +$306K 0.07% 404

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Prelude Capital Management's ECYT Position: Q4 2018 in Review

Prelude Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 44,284 shares — an estimated $786K sold.

Prelude Capital Management first reported a position in ECYT in Q1 2014 and held it in 11 quarters. The position peaked at $786K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Prelude Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 44,284 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $786K.
  • Prelude Capital Management first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 11 quarters.
  • Prelude Capital Management's Endocyte, Inc. Common Stock position peaked at $786K in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.